biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Deal Metrics

<< Previous

Bullboard Posts

Next >>

Comment by KayakerBCon Dec 13, 2022 12:05pm

146 Views

Post# 35168694

RE:Deal Metrics

Barsax,

And as per the [url= https://stockhouse.com/companies/bullboard/v.bti/bioasis-technologies-inc?postid=35168354]Reuters[/url] info.....

MIDATECH PHARMA PLC - PROPOSED DEAL FOR CONSIDERATION OF, IN AGGREGATE, APPROXIMATELY C$7.4 MILLION

7,400,000 / 75,900,000 BTI shares = .0975 CDN

which is close to the .09 CDN in the Midatech doc.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?